CWP232228 | CAS# 1144044-02-9 | Wnt/β-Catenin inhibitor

MedKoo Cat#: 563772 | Name: CWP232228 sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CWP232228 is a novel Wnt/β-Catenin inhibitor. It preferentially inhibits the growth of breast cancer stem-like cells. CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment.

Chemical Structure

CWP232228 sodium

CAS#1144044-02-9 (sodium)

Theoretical Analysis

MedKoo Cat#: 563772

Name: CWP232228 sodium

CAS#: 1144044-02-9 (sodium)

Chemical Formula: C33H34N7Na2O7P

Exact Mass:

Molecular Weight: 717.63

Elemental Analysis: C, 55.23; H, 4.78; N, 13.66; Na, 6.41; O, 15.61; P, 4.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

1144044-02-9 (sodium) 1144045-59-9 (free acid)

Synonym

CWP232228; CWP-232228; CWP 232228; CWP232228 sodium,

IUPAC/Chemical Name

Sodium 4-(((6S,9aS)-2-Allyl-1-(benzylcarbamoyl)-8-((2-methyl-2H-indazol-7-yl)methyl)-4,7-dioxooctahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl phosphate

InChi Key

KKMKZLQVDAGSOA-GDUXWEAWSA-L

InChi Code

InChI=1S/C33H36N7O7P.2Na/c1-3-16-38-22-30(41)39-28(17-23-12-14-27(15-13-23)47-48(44,45)46)32(42)37(20-26-11-7-10-25-19-36(2)35-31(25)26)21-29(39)40(38)33(43)34-18-24-8-5-4-6-9-24;;/h3-15,19,28-29H,1,16-18,20-22H2,2H3,(H,34,43)(H2,44,45,46);;/q;2*+1/p-2/t28-,29-;;/m0../s1

SMILES Code

O=P([O-])([O-])OC1=CC=C(C[C@H](N2[C@@](CN3CC4=CC=CC5=CN(C)N=C45)([H])N(C(NCC6=CC=CC=C6)=O)N(CC=C)CC2=O)C3=O)C=C1.[Na+].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 717.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Jang GB, Hong IS, Kim RJ, Lee SY, Park SJ, Lee ES, Park JH, Yun CH, Chung JU, Lee KJ, Lee HY, Nam JS. Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells. Cancer Res. 2015 Apr 15;75(8):1691-702. doi: 10.1158/0008-5472.CAN-14-2041. Epub 2015 Feb 6. PubMed PMID: 25660951. 2: Kim JY, Lee HY, Park KK, Choi YK, Nam JS, Hong IS. CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment. Oncotarget. 2016 Apr 12;7(15):20395-409. doi: 10.18632/oncotarget.7954. PubMed PMID: 26967248; PubMed Central PMCID: PMC4991463. 3: Benoit YD, Mitchell RR, Risueño RM, Orlando L, Tanasijevic B, Boyd AL, Aslostovar L, Salci KR, Shapovalova Z, Russell J, Eguchi M, Golubeva D, Graham M, Xenocostas A, Trus MR, Foley R, Leber B, Collins TJ, Bhatia M. Sam68 Allows Selective Targeting of Human Cancer Stem Cells. Cell Chem Biol. 2017 Jul 20;24(7):833-844.e9. doi: 10.1016/j.chembiol.2017.05.026. Epub 2017 Jun 22. PubMed PMID: 28648376. 4: Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. 2017 Nov;51(5):1357-1369. doi: 10.3892/ijo.2017.4129. Epub 2017 Sep 19. Review. PubMed PMID: 29048660; PubMed Central PMCID: PMC5642388. 5: Katoh M. Multi-layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β-catenin signaling activation (Review). Int J Mol Med. 2018 Aug;42(2):713-725. doi: 10.3892/ijmm.2018.3689. Epub 2018 May 17. PubMed PMID: 29786110; PubMed Central PMCID: PMC6034925.